{"title":"Roles of the nonvisual opsins in the mammalian retina.","authors":"Russell N VAN Gelder","doi":"10.1016/B978-0-443-22193-4.00021-4","DOIUrl":"10.1016/B978-0-443-22193-4.00021-4","url":null,"abstract":"<p><p>In addition to the rods and cones that subserve vision, several classes of mammalian retinal ganglion cells are also directly photoreceptive. These \"intrinsically photosensitive\" retinal ganglion cells (\"ipRGCs\") utilize the nonvisual photopigments melanopsin (Opn4), neuropsin (Opn5), and encephalopsin (Opn3), which are expressed in largely nonoverlapping ganglion cell populations. Remarkably, all three nonvisual opsins appear to influence the circadian clock, but in different ways. Opn4-expressing cells project from the retina to brain regions regulating circadian rhythms, such as the suprachiasmatic nuclei, and are necessary for entrainment of the behavioral clock in mammals to external light-dark cycles. The retina itself is also a functioning circadian clock, and its local entrainment is mediated by Opn5-dependent photoreception. While evidence for Opn3 functioning as a nonvisual photoreceptor is more limited, loss of its function impairs the amplitude of the circadian clock in multiple tissues, including the retina. These opsins also have other functions within and outside the eye, with Opn4-expressing cells in particular having been shown to influence form vision. This review summarizes current understanding of the biochemistry, cell biology, and physiology of the three nonvisual opsins in the retina.</p>","PeriodicalId":12907,"journal":{"name":"Handbook of clinical neurology","volume":"217 ","pages":"169-177"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147863958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Retinal cell types: Rod and cone photoreceptors.","authors":"Zander Esh, Vladimir J Kefalov","doi":"10.1016/B978-0-443-22193-4.00011-1","DOIUrl":"10.1016/B978-0-443-22193-4.00011-1","url":null,"abstract":"<p><p>This chapter outlines the current understanding on several key topics in the field of rod and cone photoreceptor research. First, we discuss the research techniques that have led to the knowledge accumulated to date, as well as novel approaches to studying photoreceptors. Next, we outline photoreceptor development followed by the mature photoreceptor anatomy. The bulk of the chapter addresses the physiology of photoreceptors, first examining the unique electrophysiologic properties of rod and cone photoreceptors and then discussing their functional characteristics that enable dim- and bright-light vision. We then discuss cellular metabolism and the unique energy requirement of photoreceptors for sustaining their function. Finally, we examine diseases that affect the human photoreceptors, with an emphasis on the genetic bases and pathophysiology as it relates to the functional characteristics described earlier in the chapter. The chapter ends with a short note on the future directions of photoreceptor research and the emerging therapeutics that will be available to clinicians in the coming years.</p>","PeriodicalId":12907,"journal":{"name":"Handbook of clinical neurology","volume":"217 ","pages":"113-128"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147863974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Genetics of the retina.","authors":"Yasmine Zaydon, Fabiha Ahmed, Stephen Tsang","doi":"10.1016/B978-0-443-22193-4.00012-3","DOIUrl":"10.1016/B978-0-443-22193-4.00012-3","url":null,"abstract":"<p><p>The retina is a vital component of the visual system, converting light into neural signals processed by the brain. Its structure includes photoreceptors, bipolar cells, and ganglion cells, each contributing to vision. Genetics play a critical role in retinal development and health, with mutations in over 270 genes linked to inherited retinal diseases, such as retinitis pigmentosa (RP), age-related macular degeneration (AMD), and Leber congenital amaurosis (LCA). These conditions range from mild visual impairment to complete blindness, reflecting the genetic diversity underlying retinal diseases. Progress in molecular biology has improved understanding of how genetic mutations disrupt retinal function. For example, RP involves mutations in RHO, USH2A, and RPGR, leading to progressive photoreceptor degeneration. AMD is associated with variations in CFH and ARMS2, driven by both genetic and environmental factors. Next-generation sequencing and gene therapy have enabled more targeted treatments. Continued research into retinal implants, pharmacologic interventions, and mitochondrial therapies is expanding therapeutic options, providing hope for improved outcomes and preservation of vision in individuals with these genetic conditions.</p>","PeriodicalId":12907,"journal":{"name":"Handbook of clinical neurology","volume":"217 ","pages":"21-33"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147863732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Fundus autofluorescence imaging.","authors":"Jodi Hwang, Hossein Ameri","doi":"10.1016/B978-0-443-22212-2.00023-9","DOIUrl":"10.1016/B978-0-443-22212-2.00023-9","url":null,"abstract":"<p><p>Fundus autofluorescence (FAF) is a widely utilized method of imaging the retina. It provides a quick and noninvasive method to assess the health of the photoreceptor and retinal pigment epithelium. FAF enables topographic mapping of the metabolic profile of the retina, allowing for disease detection, prognosis, and guidance for the management of a variety of retinal and choroidal diseases. Short-wavelength autofluorescence is the most widely used and studied method of FAF, though advanced techniques such as near-infrared autofluorescence may further expand the clinical utilities of FAF.</p>","PeriodicalId":12907,"journal":{"name":"Handbook of clinical neurology","volume":"218 ","pages":"87-108"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148101492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Human brain evolution: Role of SINE-VNTR-Alu retrotransposons and SINE-VNTR-Alu long noncoding RNA AK057321.","authors":"Matthew P Anderson, Y I Nong","doi":"10.1016/B978-0-443-19043-8.00025-6","DOIUrl":"https://doi.org/10.1016/B978-0-443-19043-8.00025-6","url":null,"abstract":"<p><p>Humans differ remarkably from great apes, with advanced cognitive abilities correlated to enlarged brains resulting from prolonged neurodevelopment. The SINE-VNTR-Alu (SVA) retrotransposons are candidate genetic drivers of these differences. Human genes with intronic SVAs are enriched for neurodevelopmental diseases; the microcephaly gene CDK5 regulatory subunit associated protein 2 (CDK5RAP2) and epilepsy/intellectual disability gene SCN8A coding for sodium channel subunit contain human-specific, intronic SVAs. Deleting gene ZNF91 coding for the SVA-binding zinc finger protein 91 or the intronic SVAs upregulate gene expression to accelerate functional and structural neuron maturation. We also discovered the function of AK057321, duplicated in ultrarare autism, founding a new gene family of long noncoding RNAs containing SVA sequences. AK057321 increases 10-fold as progenitors mature into glutamatergic neurons, and its premature increase upregulates CDK5RAP2 and SCN8A to accelerate neuron maturation. As anticipated by its sequence complementarity, AK057321 forms RNA:DNA heteroduplexes with genomic SVAs and decoy-binds the ZNF91 repressive complex. SVA-mediated block of CDK5RAP2-induced neuron maturation could prolong progenitor proliferation to increase neuron numbers and cerebral cortex size. SVA-lncRNA AK057321 also acts in adulthood to promote threefold enriched expression of Huntington (containing an SVA) in the frontal cortex relative to the brain stem. The large number of neurologic genes regulated by SVA-lncRNA AK057321 suggests the retrotransposon-based gene regulatory mechanism shaped human brain development and functions to advance cognitive abilities.</p>","PeriodicalId":12907,"journal":{"name":"Handbook of clinical neurology","volume":"219 ","pages":"57-74"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149193015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Epigenetic processes in neurodevelopmental disorders.","authors":"Elisa Ventura, Alessandro Sessa","doi":"10.1016/B978-0-443-19043-8.00003-7","DOIUrl":"https://doi.org/10.1016/B978-0-443-19043-8.00003-7","url":null,"abstract":"<p><p>Epigenetic factors control the pattern of gene expression during brain development, introducing epigenetic modifications that can be maintained and transmitted from one cell generation to the next one or modified in response to external stimuli. Such modifications are fundamental for the correct timing and spatial regulation of the critical processes that follow one another during brain development. Proper DNA methylation, histone modification, chromatin remodeling, and noncoding RNAs function are required for the formation of a functional cortex. Since epigenetic factors control the expression of multiple genes, their alteration usually has pleiotropic effects and impacts on multiple biologic processes. Alterations affecting epigenetic factors that are relevant for brain development translate into defects in key processes, including neuronal stem cell proliferation, differentiation and maturation, neuron migration, and synapse formation/function. The dysregulation of all these processes leads to neurodevelopmental disorders with different etiology, age onset, and severity of the clinical manifestations. Despite the heterogeneity of these disorders, neurodevelopmental disorders of different origin can feature overlapping phenotypes and common symptoms, depending on the neurodevelopmental mechanisms that are impacted by the specific altered epigenetic factor.</p>","PeriodicalId":12907,"journal":{"name":"Handbook of clinical neurology","volume":"219 ","pages":"187-203"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149193019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.","authors":"Albert Aboseif, Eoin P Flanagan","doi":"10.1016/B978-0-323-90887-0.00010-9","DOIUrl":"10.1016/B978-0-323-90887-0.00010-9","url":null,"abstract":"<p><p>B lymphocytes are essential to the adaptive immune system with several key functions involving antibody production, pro- and anti-inflammatory cytokine production, and antigen presentation to CD4+ T cells. These functions are critical in promoting downstream effector mechanisms underlying the pathogenesis of many autoimmune neurologic disorders. Inhibiting B cells with monoclonal antibodies has been successful in a variety of autoimmune neurologic disorders, including diseases thought to be primarily T-cell mediated. B-cell depletion is now commonly utilized in clinical practice with approved medications for multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Moreover, clinical trials are underway involving several other disorders including autoimmune encephalitis. Their effectiveness has led to the development of a variety of B-cell targeting treatments that differ by antigenic target, form (humanized or chimeric), route of administration, and dosing frequency. Additionally, there has been an increase in their affordability via biosimilars, allowing for increased accessibility globally. With their increasing use, it is important to be aware of their side-effect profile, associated risk of infection, and their use in special populations. Anti-B-cell therapies have revolutionized our therapeutic approach to autoimmune disorders of the central nervous system and their high efficacy has led to an overall benefit in patients afflicted by these conditions.</p>","PeriodicalId":12907,"journal":{"name":"Handbook of clinical neurology","volume":"214 ","pages":"107-123"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aditi Sharma, Tammy L Smith, John E Greenlee, Stacey L Clardy
{"title":"The history of paraneoplastic neurologic disorders of the CNS, PNS, and autonomic nervous systems: Perspective on the past toward a brighter future.","authors":"Aditi Sharma, Tammy L Smith, John E Greenlee, Stacey L Clardy","doi":"10.1016/B978-0-323-90887-0.00005-5","DOIUrl":"10.1016/B978-0-323-90887-0.00005-5","url":null,"abstract":"<p><p>Cases of paraneoplastic neurologic disease were described as early as the 1800s; despite two centuries of impressive progress in our understanding of immunity, autoimmunity, and paraneoplastic antibodies, we still have a lot to learn about these rare and devastating diseases. This chapter focuses on the history of paraneoplastic neurologic diseases of the central, peripheral, and autonomic nervous systems. Rather than attempting an exhaustive chronicle of every antibody discovered to date, we discuss key discoveries and concepts which laid the groundwork for our current understanding of paraneoplastic neurologic disease as a whole. The work of the pioneers described in this chapter, as well as many others, provides the foundation upon which future work in this field will be built. Reflecting on the incremental nature of scientific discovery, the critical observations which allowed for paradigm shifts, and the gaps in our current knowledge provides valuable lessons for future directions in this field.</p>","PeriodicalId":12907,"journal":{"name":"Handbook of clinical neurology","volume":"214 ","pages":"27-44"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Immunotherapies in autoimmune inflammatory myopathies: Rationale and therapeutic updates.","authors":"Goran Rakocevic, Marinos C Dalakas","doi":"10.1016/B978-0-323-90887-0.00008-0","DOIUrl":"10.1016/B978-0-323-90887-0.00008-0","url":null,"abstract":"<p><p>Autoimmune inflammatory myopathies (AIM) constitute a heterogeneous group of acquired myopathies with endomysial inflammation as a shared feature highlighting a potentially autoimmune inflammatory process amenable to immunotherapies. The disorders can be best classified as dermatomyositis, necrotizing autoimmune myositis, antisynthetase syndrome-overlap myositis, and inclusion body myositis. Because of clinical and immunohistologic heterogeneity but often overlapping pathophysiologic features among all major subsets, a correct diagnosis is critical from the outset to apply the most suitable and subset-specific immunotherapy. Advances in the immunopathologic characterization of autoimmune inflammatory myopathies have identified potentially mechanism-specific disease subsets that promise the application of targeted immunotherapies for better clinical outcomes. A number of recent clinical trials with biologic agents and monoclonal antibodies, regardless of the clinical outcome considering that several were negative, have collectively expanded our knowledge on the main pathogenic markers of autoimmunity associated with each AIM subset including the role of T-cell or B-cell factors, key cytokines, complement and various associated antibodies, or innate immunity factors. The paper summarizes the main clinical and histopathologic features of each myositis subtype, including overlapping or unique concepts of their immunopathogenic mechanisms, being mainly focused on applied immunotherapies and relevant controlled clinical trials discussing evidence-based efficacy according to the currently evolved therapeutic algorithm. The ongoing trials are also discussed highlighting those with promising future, if applied early in the disease, and the new immunotherapeutic interventions for the refractory AIM subsets.</p>","PeriodicalId":12907,"journal":{"name":"Handbook of clinical neurology","volume":"214 ","pages":"417-436"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing misconceptions.","authors":"Richard K Burt, Tobias Alexander","doi":"10.1016/B978-0-323-90887-0.00020-1","DOIUrl":"10.1016/B978-0-323-90887-0.00020-1","url":null,"abstract":"<p><p>Autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis (MS) is the technique of administrating a short immunosuppressive regimen over 4-6 days (depending on the drug regimen) followed by intravenous infusion of one's own hematopoietic stem cells to hasten hematopoietic recovery. The toxicity and efficacy of the procedure depend on the regimen and on patient selection and, to a lesser extent, on center experience. MS-specific nonmyeloablative regimens are less toxic and safer than myeloablative regimens that were initially developed for cancer. To date, there have been no randomized trials comparing the different regimens. HSCT like all immune-based therapy is more effective for the inflammatory phase of MS. It is effective for relapsing-remitting MS, less effective for active secondary progressive MS (SPMS), and almost ineffective for nonactive SPMS and primary progressive MS. Effectiveness and superiority of HSCT have been reported in a phase III randomized trial against the best available disease-modifying therapies at that time (mostly natalizumab) and in large meta-analyses. Compared to disease-modifying therapies, HSCT demonstrates posttransplant drug-free meaningful improvement of neurologic disability and quality of life for prolonged long-term follow-up in most patients.</p>","PeriodicalId":12907,"journal":{"name":"Handbook of clinical neurology","volume":"214 ","pages":"191-216"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}